Want to see GB:AZN full AI Analyst Report?

AstraZeneca (AZN) Share Forecast & Price Target

964 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Strong Buy

13 Buy

1 Hold

1 Sell

Based on 15 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

16,126.43 p

▲(6.67% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 16,126.43 p with a high forecast of 18,900.00 p and a low forecast of 11,300.00 p. The average price target represents a 6.67% change from the last price of 15,118.00 p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10222":"10,222 p","18901":"18,901 p","12391.75":"12,391.8 p","14561.5":"14,561.5 p","16731.25":"16,731.3 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">19K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16126.42857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">16K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[10222,12391.75,14561.5,16731.25,18901],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13854,14242.153846153846,14630.307692307691,15018.461538461539,15406.615384615385,15794.76923076923,16182.923076923076,16571.076923076922,16959.23076923077,17347.384615384617,17735.53846153846,18123.69230769231,18511.846153846152,{"y":18900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13854,14028.802197802197,14203.604395604396,14378.406593406593,14553.208791208792,14728.010989010989,14902.813186813186,15077.615384615385,15252.417582417582,15427.21978021978,15602.021978021978,15776.824175824175,15951.626373626374,{"y":16126.42857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13854,13657.538461538461,13461.076923076924,13264.615384615385,13068.153846153846,12871.692307692309,12675.23076923077,12478.76923076923,12282.307692307691,12085.846153846154,11889.384615384615,11692.923076923078,11496.461538461539,{"y":11300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10223.814,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10913.788,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11728.389,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12308.375,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12342.026,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13694.008,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13648.479,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13895.914,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15252,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15022,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13512,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13434,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13854,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target18,900 p

Average Price Target16,126 p

Lowest Price Target11,300 p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

11,500 p

Sell

-23.93%

Downside

Reiterated

07/10/26

Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)

Graham Parry

Citi

18,000 p→17,500 p

Buy

15.76%

Upside

Reiterated

07/10/26

AstraZeneca (AZN) Receives a Buy from Citi

Seamus Fernandez

Guggenheim

16,500 p→16,200 p

Buy

7.16%

Upside

Reiterated

07/09/26

Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)

Justin Smith

Bernstein

18,900 p

Buy

25.02%

Upside

Reiterated

07/09/26

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

16,000 p

Buy

5.83%

Upside

Reiterated

07/09/26

J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

16,370 p

Buy

8.28%

Upside

Reiterated

07/09/26

Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)

Sachin Jain

Bank of America Securities

16,500 p

Buy

9.14%

Upside

Reiterated

07/09/26

AstraZeneca: Buy Rating Reaffirmed as Diversified Pipeline Offsets CARDIO-TTRansform Setback; 16,500 GBp Price Target Maintained

Michael Leuchten

Jefferies

18,000 p

Buy

19.06%

Upside

Reiterated

07/09/26

AstraZeneca (AZN) Gets a Buy from Jefferies

Sarita Kapila

Morgan Stanley

16,500 p

Buy

9.14%

Upside

Reiterated

07/08/26

AstraZeneca Buy Rating Reaffirmed as De‑Risked Pipeline and 2027 CRM Portfolio Support Unchanged $16,500 Price Target

Rajesh Kumar

HSBC

17,200 p→16,500 p

Buy

9.14%

Upside

Reiterated

07/06/26

AstraZeneca price target lowered to 165 GBp from 172 GBp at HSBCAstraZeneca price target lowered to 165 GBp from 172 GBp at HSBC

James Gordon CFA

Barclays

16,500 p

Buy

9.14%

Upside

Reiterated

06/30/26

AstraZeneca (AZN) Receives a Buy from Barclays

Steve Scala

TD Cowen

―

Buy

―

Reiterated

04/30/26

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)

Matthew Weston

UBS

17,600 p

Buy

16.42%

Upside

Reiterated

04/30/26

UBS Remains a Buy on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

16,400 p

Buy

8.48%

Upside

Upgraded

04/29/26

Positive Report for AstraZeneca (AZN) from DZ BANK AG

David Evans

Kepler Capital

11,300 p

Hold

-25.25%

Downside

Reiterated

04/29/26

Kepler Capital Reaffirms Their Hold Rating on AstraZeneca (AZN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

11,500 p

Sell

-23.93%

Downside

Reiterated

07/10/26

Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)

Graham Parry

Citi

18,000 p→17,500 p

Buy

15.76%

Upside

Reiterated

07/10/26

AstraZeneca (AZN) Receives a Buy from Citi

Seamus Fernandez

Guggenheim

16,500 p→16,200 p

Buy

7.16%

Upside

Reiterated

07/09/26

Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)

Justin Smith

Bernstein

18,900 p

Buy

25.02%

Upside

Reiterated

07/09/26

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

Richard Vosser

J.P. Morgan

16,000 p

Buy

5.83%

Upside

Reiterated

07/09/26

J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

16,370 p

Buy

8.28%

Upside

Reiterated

07/09/26

Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)

Sachin Jain

Bank of America Securities

16,500 p

Buy

9.14%

Upside

Reiterated

07/09/26

AstraZeneca: Buy Rating Reaffirmed as Diversified Pipeline Offsets CARDIO-TTRansform Setback; 16,500 GBp Price Target Maintained

Michael Leuchten

Jefferies

18,000 p

Buy

19.06%

Upside

Reiterated

07/09/26

AstraZeneca (AZN) Gets a Buy from Jefferies

Sarita Kapila

Morgan Stanley

16,500 p

Buy

9.14%

Upside

Reiterated

07/08/26

AstraZeneca Buy Rating Reaffirmed as De‑Risked Pipeline and 2027 CRM Portfolio Support Unchanged $16,500 Price Target

Rajesh Kumar

HSBC

17,200 p→16,500 p

Buy

9.14%

Upside

Reiterated

07/06/26

AstraZeneca price target lowered to 165 GBp from 172 GBp at HSBCAstraZeneca price target lowered to 165 GBp from 172 GBp at HSBC

James Gordon CFA

Barclays

16,500 p

Buy

9.14%

Upside

Reiterated

06/30/26

AstraZeneca (AZN) Receives a Buy from Barclays

Steve Scala

TD Cowen

―

Buy

―

Reiterated

04/30/26

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)

Matthew Weston

UBS

17,600 p

Buy

16.42%

Upside

Reiterated

04/30/26

UBS Remains a Buy on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

16,400 p

Buy

8.48%

Upside

Upgraded

04/29/26

Positive Report for AstraZeneca (AZN) from DZ BANK AG

David Evans

Kepler Capital

11,300 p

Hold

-25.25%

Downside

Reiterated

04/29/26

Kepler Capital Reaffirms Their Hold Rating on AstraZeneca (AZN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months

Emmanuel PapadakisDeutsche Bank

Success Rate

37/59 ratings generated profit

Average Return

+4.55%

Copying Emmanuel Papadakis's trades and holding each position for 3 Months would result in 62.71% of your transactions generating a profit, with an average return of +4.55% per trade.

1 Year

Matthew WestonUBS

Success Rate

34/39 ratings generated profit

Average Return

+15.95%

Copying Matthew Weston's trades and holding each position for 1 Year would result in 87.18% of your transactions generating a profit, with an average return of +15.95% per trade.

2 Years

Matthew WestonUBS

Success Rate

34/39 ratings generated profit

Average Return

+21.52%

Copying Matthew Weston's trades and holding each position for 2 Years would result in 87.18% of your transactions generating a profit, with an average return of +21.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 40 Buy Ratings, 0 Hold Ratings, and 8 Sell Ratings. AZN average Analyst price target in the past 3 months is 16,126.43.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.86 p with a range of 1.78 p to 1.93 p. The previous quarter’s EPS was 1.93 p. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 11.54B with a range of 11.37B to 11.72B . The previous quarter’s sales results were 11.35B . AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca plc’s 12-month average price target is 16,126.43.

What is GB:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca plc has 6.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca plc a Buy, Sell or Hold?

AstraZeneca plc has a consensus rating of Strong Buy, which is based on 13 buy ratings, 1 hold ratings and 1 sell ratings.

What is AstraZeneca plc’s share price target?

The average share price target for AstraZeneca plc is 16,126.43. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 18,900.00 p ,and the lowest forecast is 11,300.00 p. The average share price target represents 6.67% Increase from the current price of 15,118 p.

What do analysts say about AstraZeneca plc?

AstraZeneca plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AstraZeneca plc?

To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (AZN) Share Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Detailed List of Analyst Forecasts